retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide: A Promising Option for

Tirzepatide microdosing example Strategy A: Titration with smaller increments (compounded version) Tirzepatide come in the form of prefilled pens in fixed, single-use doses (e.g., 2.5 mg, 5 mg, etc.)

They used a mouse model of diet-induced obesity and combined metabolomic analyses in BAT and other tissues with stable-isotope tracer studies to answer this question

While SURPASS-4 was not powered to evaluate differences in MACE-4 incidence between tirzepatide treatment groups and glargine, it was designed to fulfill the MACE-4 non-inferiority analysis requested by regulatory authorities to evaluate the cardiovascular safety of new glucose lowering medications

Experts stress caution in extrapolating these findings to humans and call for clinical trials to clarify how weight loss drugs affect muscle size and strength

The program is designed for individuals with a BMI of 21 or higher, representing the vast majority of US adults

These are generally most pronounced when starting or increasing doses and tend to diminish over time as the body adjusts